ITGAX and neoplasm: The abundance of CD24+MHC-II+CD11c+ cells in the circulation of tumour-bearing mice treated with the combination therapy was 2.0- and 1.4-fold higher than that in control or IRE monotherapy-treated mice, respectively (Fig. 6g and Supplementary Fig. 21a).